Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

On March 17, 2023 Keymed Biosciences Inc. (HKEX: 02162) reported its 2022 annual results (Press release, Keymed Biosciences, MAR 17, 2023, View Source;proactively-develops-global-strategic-collaboration-301775097.html [SID1234628997]). Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and accelerate its commercialization progress in 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of Innovative and Differentiated Pipelines

Core Product CM310 (IL-4Rα antibody):

Initiated Phase III registrational clinical trial for adults with moderate to severe AD in 2022 Q1; Completed the patient enrollment in 2022 November; The Company plans to complete this trial and submit the NDA for this indication in 2023.
Released Phase II clinical data for the treatment of CRSwNP in end of March 2022: co-primary efficacy endpoints are fully achieved with positive results; Initiated Phase III trial in 2022 H2.
Received Breakthrough therapy designation (BTD) from the CDE for the treatment of moderate to severe AD in June 2022.
Obtained the CDE IND approval for the treatment of AR in July 2022.
Obtained the FDA IND approval for the treatment of AD in August 2022.
Initiated Phase II/III pivotal clinical trial for moderate to severe asthma in March 2023, led by CSPC.
Core Product CM326 (TSLP antibody):

Initiated Phase Ib/IIa clinical trial for patients with moderate to severe AD in 2022 H1; Simultaneously initiated Phase II clinical trial for adults with moderate to severe AD in 2022 H2.
Initiated Phase Ib/IIa clinical trial for patients with CRSwNP in 2022 H2; Completed the patient enrollment in February 2023.
Core Product CMG901 (Claudin 18.2 ADC):

Completed the patients enrollment of Phase Ia dose-escalation clinical trial in subjects with solid tumor by 2022 H1; Initiated Phase Ib dose-expansion clinic trial in 2022 Q2 and patient enrollment for this trial is ongoing.
Received Orphan-drug Designation & Fast Track Designation for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer from the FDA in April 2022.
Received Breakthrough therapy designation (BTD) for the treatment of Claudin 18.2-positive advanced gastric cancer from the CDE in September 2022.
Presented Phase Ia clinical data in subjects with advanced solid tumor at the 2023 ASCO (Free ASCO Whitepaper) GI in January 2023: The results showed that CMG901 was well-tolerated with a favorable safety profile; Preliminary efficacy results demonstrated that in the 8 Claudin 18.2-positive gastric/GEJ cancer patients receiving CMG901, Objective response rate (ORR) and disease control rate (DCR) were 75.0% and 100%, respectively, with ORR of 100% in the 2.6, 3.0, and 3.4 mg/kg cohorts.
In February 2023, KYM Biosciences Inc. (a non-wholly owned subsidiary owned by Keymed with 70% shares) entered a global exclusive license agreement with AstraZeneca AB, who will be responsible for the research, development, manufacture, and commercialization of CMG901 globally. Under the terms of the agreement, KYM Biosciences will receive an upfront payment of $63m on transaction closing and additional development and sales-related milestone payments of up to $1.1bn as well as tiered royalties up to low double-digits.
Core Product CM313 (CD38 antibody):

Proceeding Phase Ia does-escalation clinical trial for RRMM in 2022; Initiated dose expansion clinical trial in the late stage of 2022 Q1.
Obtained IND approval for the treatment of SLE in China in April 2022; completed the first patient dosing in October 2022; Phase Ib/IIa clinical trial is ongoing.
Core Product CM338 (MASP-2 antibody):

Completed CM338 Phase I clinical trial with healthy volunteers in November 2022.
Initiated CM338 Phase II clinical trial for the treatment of IgAN in March 2023.
Other Assets

CM355 (CD20xCD3):

Completed the first patient dosing in January 2022; Phase I dose-escalation trial is ongoing.
CM336 (BCMAxCD3):

Completed the first patient dosing in September 2022; Phase I dose-escalation trial is ongoing.
CM350 (GPC3xCD3):

Obtained IND approval in China for the treatment of solid tumor in January 2022; Completed the first patient dosing in May 2022; Phase I dose-escalation trial is ongoing.
CM369 (CCR8 antibody):

Obtained IND approval in China for the treatment of advanced solid tumor in August 2022; Completed the first patient dosing in January 2023; Phase I dose-escalation trial is ongoing.
Enlarged Team of Talents & Expanded Manufacturing Capabilities

The Company has built a stable core team and continuously recruit talents to match its growing demand for R&D, clinical trial, manufacture, operation and commercialization. By December 31th 2022, the Company has a total of 613 employees, including over 240 employees in clinical development and operations, and more than 230 employees in production and quality control, with a year-over-year increase of 189%.
In addition to the headquarters in Chengdu, the Company has set offices in Shanghai, Beijing, Wuhan, Guangzhou, Nanjing, Jinan.
The construction of the first phase of commercial-scale facility has been completed by the end of 2022, which will provide 16,000L of manufacturing capacity. The design of all facilities is in compliance with the requirements of cGMP of the NMPA and FDA.
Financial Data & Capital Market Performance

As of December 31, 2022, the Company’s R&D investment amounted RMB 500 million, a year-over-year increase of 42%; Income amounted RMB 100 million, which comes from the out-licensing revenue of CM326 from CSPC; The Company holds a total of RMB 3.17 billion in cash and cash equivalents, time deposits and bank wealth management, which can fully support the Company’s future development.
In March 2022, Keymed Bio (2162.HK) was included as eligible stocks of the Shenzhen-Hong Kong Stock Connect. In Aug 2022, Keymed got listed in FTSE Global Small Cap Index ex US; In Nov 2022, Keymed got listed in MSCI China Small Cap Index.

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On March 17, 2023 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, reported the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company’s 2016 Equity Incentive Plan, but under the terms of the company’s 2018 Equity Inducement Plan (Press release, Aeglea BioTherapeutics, MAR 17, 2023, View Source [SID1234628996]). The awards were granted as material inducements to the employees entering into employment with Aeglea in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Aeglea, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Aeglea, pursuant to Nasdaq Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 63,000 shares of Aeglea’s common stock. The options have an exercise price of $0.31 per share, which is equal to the closing price of Aeglea’s common stock on March 17, 2023. The option awards vest at 25% of the shares on the one-year anniversary of the grant, with the remainder of the shares vesting ratably over 36 months thereafter subject to each employees’ continued employment through the applicable vesting date. The awards are subject to the terms and conditions of the 2018 Equity Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On March 17, 2023 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors (i) granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units (RSUs) of Sutro common stock in connection with her appointment as Sutro’s Chief Medical Officer and (ii) granted 10,000 RSUs of Sutro common stock to one other new employee (Press release, Sutro Biopharma, MAR 17, 2023, View Source [SID1234628994]). These grants were made as an inducement material to the employees’ acceptance of employment with Sutro and were approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The RSUs and stock options are subject to the terms and conditions of Sutro’s 2021 Equity Inducement Plan. One-fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the employee’s hire date and annually thereafter until fully vested on the fourth anniversary, subject to the employee’s continued service with Sutro on each such vesting date. One-fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s hire date and 1/48th of the total number of shares underlying the stock options will vest each month thereafter until fully vested on the fourth anniversary of the employee’s hire date, subject to the employee’s continued service with Sutro on each such vesting date. The stock options have a term of ten years and an exercise price equal to the closing price of Sutro’s common stock on the grant date as reported by The Nasdaq Stock Market.

VerImmune Inc Announces Upcoming Oral and Poster Presentations at the 35th IPV and AACR Annual meeting 2023

On March 17, 2023 VerImmune, Inc. ("VerImmune"), an innovative biotechnology company leading the way in developing virus-inspired particle modalities for cancer treatment is reported the publication of scientific abstracts for an upcoming Oral presentation at the 35th International Papillomavirus Conference taking place April 17-21 in Washington DC as well as a Poster presentation at the American Associate for Cancer Research Annual 2023 Meeting, taking place April 14-19 in Orlando, Florida (Press release, VerImmune, MAR 17, 2023, View Source [SID1234628993]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the Oral and Poster presentations are as follows:

American Associate for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting

Published Abstract Number: 1854

Title: CANCER TREATMENT UTILIZING VIRUS-INSPIRED PARTICLES FOR THE REDIRECTION OF IMMUNE MEMORY

Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 2
Session Date and Time: Monday Apr 17, 2023 9:00 AM – 12:30 PM
Location: Poster Section 24
Poster Board Number: 26

35th International Papillomavirus Conference

Title: REDIRECTING PRE-EXISTING VIRAL IMMUNITY TOWARDS CANCERS VIA MURINE PAPILLOMAVIRUS T=1 VIRUS-INSPIRED PARTICLES (VIPS)

Session Name: BASIC SCIENCE ORAL: IMMUNOLOGY & VACCINES
Session Type: Basic Science Oral Abstracts Session
Session Date and time: April 21st 2023; 08:00 – 09:30
Location Room 207A

Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

On March 17, 2023 Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific (Press release, Spectrum Pharmaceuticals, MAR 17, 2023, View Source [SID1234628992]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast:

Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific

To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the call will be available online in the Investor Relations section of the company’s website at View Source and will be archived there shortly after the live event.